Angiotensin Receptor Antagonists

"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.

Descriptor ID	D057911
MeSH Number(s)	D27.505.519.162
Concept/Terms	Angiotensin Receptor Antagonists Angiotensin Receptor Antagonists Antagonists, Angiotensin Receptor Receptor Antagonists, Angiotensin Angiotensin Receptor Blockers Receptor Blockers, Angiotensin Angiotensin II Receptor Antagonists Angiotensin II Receptor Antagonists Angiotensin II Receptor Blockers

Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Angiotensin Receptor Antagonists [D27.505.519.162]

Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.

Bar chart showing 61 publications over 21 distinct years, with a maximum of 10 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	1	1	2
1999	1	0	1
2002	0	2	2
2003	0	5	5
2004	1	1	2
2007	1	2	3
2010	0	2	2
2011	1	0	1
2012	0	1	1
2013	0	2	2
2014	1	2	3
2016	1	3	4
2017	0	1	1
2018	2	0	2
2019	1	3	4
2020	1	3	4
2021	4	2	6
2022	2	8	10
2024	1	3	4
2025	1	0	1

Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.

Severino P, D'Amato A, Prosperi S, Mariani MV, Cesti? C, Myftari V, Labbro Francia A, Marek-Iannucci S, Manzi G, Filomena D, Maestrini V, Mancone M, Badagliacca R, Vizza CD, Fedele F. The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and Angiotensin Receptor-neprylisin Inhibitors in Acute Heart Failure (PENTA-HF). Curr Vasc Pharmacol. 2025; 23(3):213-223.

View in: PubMed
Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker GM, Pina IL, Granger CB, Hernandez AF, DeVore AD. Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. J Am Heart Assoc. 2024 12 17; 13(24):e036998.

View in: PubMed
Fares J, El Fadel O, Zhao J, Li M, Sun J, Roman J, Loizidis G, Summer R. Mortality and Health Outcomes Among Patients With Sarcoidosis Treated With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Chest. 2025 03; 167(3):772-780.

View in: PubMed
Newman E, Kamanu C, Gibson G, Brailovsky Y. How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure. Curr Cardiol Rep. 2024 09; 26(9):995-1003.

View in: PubMed
Severino P, D'Amato A, Prosperi S, Mariani MV, Myftari V, Labbro Francia A, Cesti? C, Tomarelli E, Manzi G, Birtolo LI, Marek-Iannucci S, Maestrini V, Mancone M, Badagliacca R, Fedele F, Vizza CD. Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience. Am J Cardiovasc Drugs. 2024 Sep; 24(5):663-671.

View in: PubMed
Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB. Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension. 2023 03; 80(3):590-597.

View in: PubMed
Weight N, Moledina S, Zoccai GB, Zaman S, Smith T, Siller-Matula J, Dafaalla M, Rashid M, Nolan J, Mamas MA. Impact of pre-existing vascular disease on clinical outcomes. Eur Heart J Qual Care Clin Outcomes. 2022 12 13; 9(1):64-75.

View in: PubMed
Moledina SM, Mannan F, Weight N, Alisiddiq Z, Elbadawi A, Elgendy IY, Fischman DL, Mamas MA. Impact of QRS Duration on Non-ST-Segment Elevation Myocardial Infarction (from a National Registry). Am J Cardiol. 2022 11 15; 183:1-7.

View in: PubMed
Sahai SK, Balonov K, Bentov N, Bierle DMM, Browning LM, Cummings KC, Dougan BM, Maxwell M, Merli GJ, Oprea AD, Sweitzer B, Mauck KF, Urman RD. Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc. 2022 09; 97(9):1734-1751.

View in: PubMed
Gupta N, Settle L, Brown BR, Armaignac DL, Baram M, Perkins NE, Kaufman M, Melamed RR, Christie AB, Danesh VC, Denson JL, Cheruku SR, Boman K, Bansal V, Kumar VK, Walkey AJ, Domecq JP, Kashyap R, Aston CE. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. Crit Care Med. 2022 10 01; 50(10):e744-e758.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement